This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barletta, G. Articles by La Villa, G. Search for Related Content PubMed PubMed Citation Articles by Barletta, G. Articles by La Villa, G.

(Hypertension. 1998;31:802-808.)
© 1998 American Heart Association, Inc.

Scientific Contributions

Low-Dose C-Type Natriuretic Peptide Does Not Affect Cardiac and Renal Function in Humans

Giuseppe Barletta; Chiara Lazzeri; Sabrina Vecchiarino; Riccarda Del Bene; Gianni Messeri; Antonio Dello Sbarba; Massimo Mannelli; ; Giorgio La Villa

From the Istituto di Medicina Interna (C.L., S.V., A.D.S., G.L.V.), Istituto di Clinica Medica e Cardiologia (G.B., R.D.B.), Dipartimento di Fisiopatologia Clinica (M.M.), Unità di Endocrinologia, University of Florence School of Medicine, and Laboratorio di Endocrinologia (G.M.), Azienda Ospedaliera Careggi, Florence, Italy.

Correspondence to Giorgio La Villa, MD, Istituto di Medicina Interna, University of Florence School of Medicine, Viale Morgagni 85, I-50135 Florence, Italy. E-mail g.lavilla{at}dfc.unifi.it

Abstract—In experimental animals, C-type natriuretic peptide (CNP) has vasodilating, hypotensive, and natriuretic activities. The role of circulating CNP in the overall regulation of cardiac and renal function in humans is less defined, in both health and disease. We measured cardiac volumes, diastolic and systolic functions, systemic (Doppler echocardiography) and renal hemodynamics, intrarenal sodium handling (lithium clearance method), plasma and urinary cGMP, plasma renin concentration, and plasma aldosterone level in six healthy volunteers (mean age, 33±3 years) receiving CNP (2 and 4 pmol/kg per minute for 1 hour each) in a single-blind, placebo-controlled, random-order, crossover study. During CNP infusion, plasma CNP increased from 1.17±0.23 to 41.52±4.61 pmol/L (ie, 4- to 10-fold higher levels than those observed in disease states) without affecting plasma and urinary cGMP, cardiac volumes, dynamics of left and right heart filling, cardiac output, arterial pressure, renal hemodynamics, intrarenal sodium handling, sodium excretion, or plasma levels of renin and aldosterone. The finding that increments in plasma CNP within the pathophysiological range have no effects on systemic hemodynamics, renal function, or the renin-angiotensin system do not support the hypothesis that CNP may act as a circulating hormone in humans.

Key Words: echocardiography • hemodynamics • systole • diastole • natriuretic peptides

This article has been cited by other articles:

				T. H. Langenickel, J. Buttgereit, I. Pagel-Langenickel, M. Lindner, J. Monti, K. Beuerlein, N. Al-Saadi, R. Plehm, E. Popova, J. Tank, et al. Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B PNAS, March 21, 2006; 103(12): 4735 - 4740. [Abstract] [Full Text] [PDF]

				M. Schmitt, A. Qasem, C. McEniery, I. B. Wilkinson, V. Tatarinoff, K. Noble, J. Klemes, N. Payne, M. P. Frenneaux, J. Cockcroft, et al. Role of natriuretic peptides in regulation of conduit artery distensibility Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1167 - H1171. [Abstract] [Full Text] [PDF]

				L. R. Potter CNP, Cardiac Natriuretic Peptide? Endocrinology, May 1, 2004; 145(5): 2129 - 2130. [Full Text] [PDF]

				S. P. Wright, T. C.R. Prickett, R. N. Doughty, C. Frampton, G. D. Gamble, T. G. Yandle, N. Sharpe, and M. Richards Amino-Terminal Pro-C-Type Natriuretic Peptide in Heart Failure Hypertension, January 1, 2004; 43(1): 94 - 100. [Abstract] [Full Text] [PDF]

				A. Cataliotti, M. Giordano, E. De Pascale, G. Giordano, P. Castellino, M. Jougasaki, L. C. Costello, G. Boerrigter, T. Tsuruda, P. Belluardo, et al. CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome Am J Physiol Renal Physiol, September 1, 2002; 283(3): F464 - F472. [Abstract] [Full Text] [PDF]

				P.R Kalra, S.D Anker, A.D Struthers, and A.J.S Coats The role of C-type natriuretic peptide in cardiovascular medicine Eur. Heart J., June 2, 2001; 22(12): 997 - 1007. [PDF]

				M. L. H. Honing, P. Smits, P. J. Morrison, J. C. Burnett Jr, and T. J. Rabelink C-Type Natriuretic Peptide-Induced Vasodilation Is Dependent On Hyperpolarization in Human Forearm Resistance Vessels Hypertension, April 1, 2001; 37(4): 1179 - 1183. [Abstract] [Full Text] [PDF]

				V Gulberg, S Moller, J H Henriksen, and A L Gerbes Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure Gut, December 1, 2000; 47(6): 852 - 857. [Abstract] [Full Text] [PDF]

				G. Barletta, M. L. De Feo, R. Del Bene, C. Lazzeri, S. Vecchiarino, G. La Villa, M. L. Brandi, and F. Franchi Cardiovascular Effects of Parathyroid Hormone: A Study in Healthy Subjects and Normotensive Patients with Mild Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1815 - 1821. [Abstract] [Full Text]

				K. Morishige, H. Shimokawa, T. Yamawaki, K. Miyata, Y. Eto, T. Kandabashi, K. Yogo, T. Higo, K. Egashira, H. Ueno, et al. Local adenovirus-mediated transfer of C-type natriuretic peptide suppresses vascular remodeling in porcine coronary arteries in vivo J. Am. Coll. Cardiol., March 15, 2000; 35(4): 1040 - 1047. [Abstract] [Full Text] [PDF]